Acorda Therapeutics (ACOR) Reports Q3 Loss, Comments on Fampridine-SR
More News related to ACOR
- Leerink Swann Upgrades Acorda Therapeutics (ACOR) Two-Notches to Outperform
- Acorda (ACOR) CEO On CNBC
- Acorda (ACOR) Enters License Agreement With Biogen Idec (BIIB) For Fampridine-SR Outside the U.S.
- Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
- Acorda Therapeutic (ACOR) October volatility at 93 into PDUFA
Acorda Therapeutics (Nasdaq: ACOR) reported a Q3 net loss of $0.37, versus the consensus of a $0.37 loss. Revenues came in at $6.2 million, versus the consensus of $5.56 million.
Ron Cohen, M.D., President and CEO said "We believe that Fampridine-SR, if approved, could be a first-in-class product, as no existing therapies are indicated to improve walking or other function for people with MS. We also have had continued growth in our Zanaflex Capsules franchise, and recently announced the expansion of our commercial sales force from 32 to 65. This sales organization will provide the commercial foundation for the launch of Fampridine-SR, if approved."
Related Categories
EarningsStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
